Update (June 12, 2026): Independent Analysis Identifies Musculoskeletal AE Signal With Bedinvetmab

TL;DR

A specialist-led disproportionality analysis found that musculoskeletal adverse events were reported approximately 9-fold more frequently in Librela-treated dogs compared with six comparator OA drugs in the EudraVigilance database; an 18-member expert panel concluded strong suspicion of a causal association with accelerated joint destruction in a subset of 19 cases.

What just dropped

• Farrell M et al. Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1581490/full — disproportionality analysis of EudraVigilance database (2004-2024) and a case series of 19 client-owned dogs. A board-certified veterinary surgeon reviewed all musculoskeletal adverse event reports for Librela, Rimadyl, Metacam, Previcox, Onsior, Galliprant, and Daxocox. Primary null hypothesis: Librela's musculoskeletal adverse event reporting rate would not exceed comparators by more than 50%. The hypothesis was not supported: ligament/tendon injury, polyarthritis, fracture, musculoskeletal neoplasia, and septic arthritis were reported approximately 9-times more frequently with Librela than the combined total of comparator drugs. An 18-member independent expert panel reviewed 19 suspected musculoskeletal adverse events and unanimously concluded strong suspicion of a causal association between bedinvetmab and accelerated joint destruction.
• Werts A et al. [Zoetis, Commentary] Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1663398. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1663398/full — Zoetis response, published October 2025. Raises methodological concerns about the Farrell disproportionality analysis, noting the bedinvetmab dataset is complete in EudraVigilance while comparator datasets are substantially incomplete (carprofen alone missing >23,900 European AE reports). States that target animal safety studies with up to 10x the recommended dose across 24 dogs showed no joint risk. Notes that EMA and FDA required RPOA mentioned as a precautionary label statement while acknowledging the condition had not been reported in dogs.

Context

In December 2024, the FDA Center for Veterinary Medicine (CVM) issued an open letter to veterinarians alerting them to neurological and musculoskeletal safety signals identified through post-marketing surveillance of Librela, encompassing 18 distinct safety signals. The Farrell study — developed independently by a working group of orthopedic specialists — extends that surveillance using a specialist-reviewed dataset and an adjudicated case series, neither of which was available to the CVM's algorithmic analysis.

The Zoetis commentary challenges the pharmacovigilance methodology and argues that data incompleteness in the comparator datasets invalidates the disproportionality comparison. Both papers are peer-reviewed and available in the same Frontiers issue; clinicians should read them together for a balanced picture.

At present, no published study has met the veterinary diagnostic criteria for rapidly progressive osteoarthritis (RPOA) as defined in humans. Multiple commentaries on the Farrell paper are in circulation as of late 2025. The debate underscores the importance of prospective controlled studies.

What this changes in Bedinvetmab (Librela) Adverse Events in Dogs (https://www.thevoyage.ai/forvets/knowledge/bedinvetmab-librela-adverse-events-dogs)

The existing evergreen covers neurological and systemic adverse event signals. This cluster of 2025 papers adds a musculoskeletal dimension: a potential signal for accelerated joint destruction that is now the subject of active scientific and regulatory scrutiny. Clinicians monitoring dogs on bedinvetmab should document baseline and follow-up radiographs of affected joints where possible, per the recommendations in both the Farrell study and the Zoetis commentary, and report suspected musculoskeletal adverse events through national reporting channels.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-12-bedinvetmab-musculoskeletal-ae-signal

References

1. Farrell M et al. Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1581490. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1581490/full
2. Werts A et al. [Zoetis commentary] Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Front Vet Sci. 2025;12:1663398. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1663398/full

Changelog

• 2026-06-12: First published.

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile